Skip to main content
NCBI home page
Clinical and Diagnostic Laboratory Immunology logoLink to Clinical and Diagnostic Laboratory Immunology
. 1995 Jan;2(1):1–9. doi: 10.1128/cdli.2.1.1-9.1995

Laboratory evaluation of the inflammatory myopathies.

L G Rider 1, F W Miller 1
PMCID: PMC170091  PMID: 7719899

Abstract

The laboratory plays an important role in the diagnosis, evaluation, and classification of the heterogeneous group of diseases known as the IIM, which are characterized by chronic muscle inflammation. Serial measurements of the levels of muscle-derived enzymes in serum are the traditional laboratory studies used to follow the clinical course of patients with IIM, although other laboratory tests can also be useful in assessing myositis disease activity. Several markers of immune system activation, including cytokines and lymphocyte markers, show promise as possibly more sensitive measures of myositis disease activity. Discovery of a unique group of MSAs over the past decade has provided an immunologic basis for defining relatively homogeneous subsets of patients who share similar clinical features, disease courses, and responses to therapy. Future investigations of novel immunologic activation markers, as well as the cloning and expression of target autoantigens of the MSAs, should allow better diagnostic assays, enhanced prognosis, and a better understanding of the pathogenesis of these disorders.

Full Text

The Full Text of this article is available as a PDF (211.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arad-Dann H., Isenberg D., Ovadia E., Shoenfeld Y., Sperling J., Sperling R. Autoantibodies against a nuclear 56 kDa protein: a marker for inflammatory muscle disease. J Autoimmun. 1989 Dec;2(6):877–888. doi: 10.1016/0896-8411(89)90014-0. [DOI] [PubMed] [Google Scholar]
  2. Arahata K., Engel A. G. Monoclonal antibody analysis of mononuclear cells in myopathies. I: Quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cells. Ann Neurol. 1984 Aug;16(2):193–208. doi: 10.1002/ana.410160206. [DOI] [PubMed] [Google Scholar]
  3. Arnett F. C., Goldstein R., Duvic M., Reveille J. D. Major histocompatibility complex genes in systemic lupus erythematosus, Sjögren's syndrome, and polymyositis. Am J Med. 1988 Dec 23;85(6A):38–41. doi: 10.1016/0002-9343(88)90381-6. [DOI] [PubMed] [Google Scholar]
  4. Arnett F. C., Hamilton R. G., Roebber M. G., Harley J. B., Reichlin M. Increased frequencies of Sm and nRNP autoantibodies in American blacks compared to whites with systemic lupus erythematosus. J Rheumatol. 1988 Dec;15(12):1773–1776. [PubMed] [Google Scholar]
  5. Askari A., Vignos P. J., Jr, Moskowitz R. W. Steroid myopathy in connective tissue disease. Am J Med. 1976 Oct;61(4):485–492. doi: 10.1016/0002-9343(76)90327-2. [DOI] [PubMed] [Google Scholar]
  6. Askmark H., Osterman P. O., Roxin L. E., Venge P. Radioimmunoassay of serum myoglobin in neuromuscular diseases. J Neurol Neurosurg Psychiatry. 1981 Jan;44(1):68–72. doi: 10.1136/jnnp.44.1.68. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Baker J. R., Jr, Miller F. W., Steinberg A. D., Burman K. D. Thyroid stimulating and thyrotrophin binding-inhibitory immunoglobulin activity in patients with systemic lupus erythematosus having thyroid function abnormalities. Thyroid. 1991 Summer;1(3):229–234. doi: 10.1089/thy.1991.1.229. [DOI] [PubMed] [Google Scholar]
  8. Bardelas J. A., Winkelstein J. A., Seto D. S., Tsai T., Rogol A. D. Fatal ECHO 24 infection in a patient with hypogammaglobulinemia: relationship to dermatomyositis-like syndrome. J Pediatr. 1977 Mar;90(3):396–399. doi: 10.1016/s0022-3476(77)80700-2. [DOI] [PubMed] [Google Scholar]
  9. Behan W. M., Behan P. O. Complement abnormalities in polymyositis. J Neurol Sci. 1977 Nov;34(2):241–246. doi: 10.1016/0022-510x(77)90072-7. [DOI] [PubMed] [Google Scholar]
  10. Bernstein R. M., Morgan S. H., Chapman J., Bunn C. C., Mathews M. B., Turner-Warwick M., Hughes G. R. Anti-Jo-1 antibody: a marker for myositis with interstitial lung disease. Br Med J (Clin Res Ed) 1984 Jul 21;289(6438):151–152. doi: 10.1136/bmj.289.6438.151. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Biswas T., Miller F. W., Takagaki Y., Plotz P. H. An enzyme-linked immunosorbent assay for the detection and quantitation of anti-Jo-1 antibody in human serum. J Immunol Methods. 1987 Apr 16;98(2):243–248. doi: 10.1016/0022-1759(87)90011-1. [DOI] [PubMed] [Google Scholar]
  12. Black H. R., Quallich H., Gareleck C. B. Racial differences in serum creatine kinase levels. Am J Med. 1986 Sep;81(3):479–487. doi: 10.1016/0002-9343(86)90303-7. [DOI] [PubMed] [Google Scholar]
  13. Blüthner M., Bautz F. A. Cloning and characterization of the cDNA coding for a polymyositis-scleroderma overlap syndrome-related nucleolar 100-kD protein. J Exp Med. 1992 Oct 1;176(4):973–980. doi: 10.1084/jem.176.4.973. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Bohan A., Peter J. B., Bowman R. L., Pearson C. M. Computer-assisted analysis of 153 patients with polymyositis and dermatomyositis. Medicine (Baltimore) 1977 Jul;56(4):255–286. doi: 10.1097/00005792-197707000-00001. [DOI] [PubMed] [Google Scholar]
  15. Bohan A., Peter J. B. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975 Feb 13;292(7):344–347. doi: 10.1056/NEJM197502132920706. [DOI] [PubMed] [Google Scholar]
  16. Bohan A., Peter J. B. Polymyositis and dermatomyositis (second of two parts). N Engl J Med. 1975 Feb 20;292(8):403–407. doi: 10.1056/NEJM197502202920807. [DOI] [PubMed] [Google Scholar]
  17. Bombardieri S., Clerico A., Riente L., Del Chicca M. G., Vitali C. Circadian variations of serum myoglobin levels in normal subjects and patients with polymyositis. Arthritis Rheum. 1982 Dec;25(12):1419–1424. doi: 10.1002/art.1780251205. [DOI] [PubMed] [Google Scholar]
  18. Borleffs J. C., Derksen R. H., Bär D. P. Serum myoglobin and creatine kinase concentrations in patients with polymyositis or dermatomyositis. Ann Rheum Dis. 1987 Feb;46(2):173–174. doi: 10.1136/ard.46.2.173. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Bowyer S. L., Ragsdale C. G., Sullivan D. B. Factor VIII related antigen and childhood rheumatic diseases. J Rheumatol. 1989 Aug;16(8):1093–1097. [PubMed] [Google Scholar]
  20. Bunn C. C., Bernstein R. M., Mathews M. B. Autoantibodies against alanyl-tRNA synthetase and tRNAAla coexist and are associated with myositis. J Exp Med. 1986 May 1;163(5):1281–1291. doi: 10.1084/jem.163.5.1281. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. CLARK L. C., Jr, THOMPSON H. L., BECK E. I., JACOBSON W. Excretion of creatine and creatinine by children. AMA Am J Dis Child. 1951 Jun;81(6):774–783. doi: 10.1001/archpedi.1951.02040030788004. [DOI] [PubMed] [Google Scholar]
  22. Cavalieri R. R. The effects of nonthyroid disease and drugs on thyroid function tests. Med Clin North Am. 1991 Jan;75(1):27–39. doi: 10.1016/s0025-7125(16)30470-9. [DOI] [PubMed] [Google Scholar]
  23. Cervera R., Ramírez G., Fernández-Solà J., D'Cruz D., Casademont J., Grau J. M., Asherson R. A., Khamashta M. A., Urbano-Márquez A., Hughes G. R. Antibodies to endothelial cells in dermatomyositis: association with interstitial lung disease. BMJ. 1991 Apr 13;302(6781):880–881. doi: 10.1136/bmj.302.6781.880-a. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Craft J. Antibodies to snRNPs in systemic lupus erythematosus. Rheum Dis Clin North Am. 1992 May;18(2):311–335. [PubMed] [Google Scholar]
  25. Craft J., Mimori T., Olsen T. L., Hardin J. A. The U2 small nuclear ribonucleoprotein particle as an autoantigen. Analysis with sera from patients with overlap syndromes. J Clin Invest. 1988 Jun;81(6):1716–1724. doi: 10.1172/JCI113511. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Crowe W. E., Bove K. E., Levinson J. E., Hilton P. K. Clinical and pathogenetic implications of histopathology in childhood polydermatomyositis. Arthritis Rheum. 1982 Feb;25(2):126–139. doi: 10.1002/art.1780250203. [DOI] [PubMed] [Google Scholar]
  27. Cruzen M. E., Arfin S. M. Nucleotide and deduced amino acid sequence of human threonyl-tRNA synthetase reveals extensive homology to the Escherichia coli and yeast enzymes. J Biol Chem. 1991 May 25;266(15):9919–9923. [PubMed] [Google Scholar]
  28. De Benedetti F., De Amici M., Aramini L., Ruperto N., Martini A. Correlation of serum neopterin concentrations with disease activity in juvenile dermatomyositis. Arch Dis Child. 1993 Aug;69(2):232–235. doi: 10.1136/adc.69.2.232. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. DeVere R., Bradley W. G. Polymyositis: its presentation, morbidity and mortality. Brain. 1975 Dec;98(4):637–666. doi: 10.1093/brain/98.4.637. [DOI] [PubMed] [Google Scholar]
  30. Edwards R. H., Isenberg D. A., Wiles C. M., Young A., Snaith M. L. The investigation of inflammatory myopathy. J R Coll Physicians Lond. 1981 Jan;15(1):19–24. [PMC free article] [PubMed] [Google Scholar]
  31. Emslie-Smith A. M., Engel A. G. Microvascular changes in early and advanced dermatomyositis: a quantitative study. Ann Neurol. 1990 Apr;27(4):343–356. doi: 10.1002/ana.410270402. [DOI] [PubMed] [Google Scholar]
  32. Engel A. G., Arahata K., Emslie-Smith A. Immune effector mechanisms in inflammatory myopathies. Res Publ Assoc Res Nerv Ment Dis. 1990;68:141–157. [PubMed] [Google Scholar]
  33. Fafalak R. G., Peterson M. G., Kagen L. J. Strength in polymyositis and dermatomyositis: best outcome in patients treated early. J Rheumatol. 1994 Apr;21(4):643–648. [PubMed] [Google Scholar]
  34. Fernandez-Sola J., Pou J. C., Junyent J. M., Urbano-Manquez A. Normal creatine kinase activity in idiopathic inflammatory myopathy: does it have prognostic implications? J Rheumatol. 1991 Oct;18(10):1640–1641. [PubMed] [Google Scholar]
  35. Fraser D. D., Frank J. A., Dalakas M., Miller F. W., Hicks J. E., Plotz P. Magnetic resonance imaging in the idiopathic inflammatory myopathies. J Rheumatol. 1991 Nov;18(11):1693–1700. [PubMed] [Google Scholar]
  36. Friedman J. M., Pachman L. M., Maryjowski M. L., Radvany R. M., Crowe W. E., Hanson V., Levinson J. E., Spencer C. H. Immunogenetic studies of juvenile dermatomyositis: HLA-DR antigen frequencies. Arthritis Rheum. 1983 Feb;26(2):214–216. doi: 10.1002/art.1780260216. [DOI] [PubMed] [Google Scholar]
  37. Fudman E. J., Schnitzer T. J. Dermatomyositis without creatine kinase elevation. A poor prognostic sign. Am J Med. 1986 Feb;80(2):329–332. doi: 10.1016/0002-9343(86)90036-7. [DOI] [PubMed] [Google Scholar]
  38. Ghosh A. K., Sakhuja V., Joshi K., Gupta K. L., Chugh K. S. Acute myositis complicated by myoglobinuric acute renal failure. J Assoc Physicians India. 1993 Jul;41(7):453–454. [PubMed] [Google Scholar]
  39. Giesker D., Bowers G. N., Jr The comparative utility of serum creatine kinase versus serum aldolase in the evaluation of muscle disorders. Conn Med. 1979 Nov;43(11):699–704. [PubMed] [Google Scholar]
  40. Goldman J., Matz R., Mortimer R., Freeman R. High elevations of creatine phosphokinase in hypothyroidism. An isoenzyme analysis. JAMA. 1977 Jul 25;238(4):325–326. [PubMed] [Google Scholar]
  41. Gran J. T., Myklebust G., Johansen S. Adult idiopathic polymyositis without elevation of creatine kinase. Case report and review of the literature. Scand J Rheumatol. 1993;22(2):94–96. doi: 10.3109/03009749309095123. [DOI] [PubMed] [Google Scholar]
  42. Guzmán J., Petty R. E., Malleson P. N. Monitoring disease activity in juvenile dermatomyositis: the role of von Willebrand factor and muscle enzymes. J Rheumatol. 1994 Apr;21(4):739–743. [PubMed] [Google Scholar]
  43. Haas R. H., Dyck R. F., Dubowitz V., Pepys M. B. C-reactive protein in childhood dermatomyositis. Ann Rheum Dis. 1982 Oct;41(5):483–485. doi: 10.1136/ard.41.5.483. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Helfgott S. M., Karlson E., Beckman E. Misinterpretation of serum transaminase elevation in "occult" myositis. Am J Med. 1993 Oct;95(4):447–449. doi: 10.1016/0002-9343(93)90319-k. [DOI] [PubMed] [Google Scholar]
  45. Hernandez R. J., Sullivan D. B., Chenevert T. L., Keim D. R. MR imaging in children with dermatomyositis: musculoskeletal findings and correlation with clinical and laboratory findings. AJR Am J Roentgenol. 1993 Aug;161(2):359–366. doi: 10.2214/ajr.161.2.8333378. [DOI] [PubMed] [Google Scholar]
  46. Hinderks G. J., Frolich J. Low serum creatine kinase values associated with administration of steroids. Clin Chem. 1979 Dec;25(12):2050–2051. [PubMed] [Google Scholar]
  47. Hirakata M., Mimori T., Akizuki M., Craft J., Hardin J. A., Homma M. Autoantibodies to small nuclear and cytoplasmic ribonucleoproteins in Japanese patients with inflammatory muscle disease. Arthritis Rheum. 1992 Apr;35(4):449–456. doi: 10.1002/art.1780350415. [DOI] [PubMed] [Google Scholar]
  48. Hochberg M. C., Feldman D., Stevens M. B. Adult onset polymyositis/dermatomyositis: an analysis of clinical and laboratory features and survival in 76 patients with a review of the literature. Semin Arthritis Rheum. 1986 Feb;15(3):168–178. doi: 10.1016/0049-0172(86)90014-4. [DOI] [PubMed] [Google Scholar]
  49. Hochberg M. C., Feldman D., Stevens M. B., Arnett F. C., Reichlin M. Antibody to Jo-1 in polymyositis/dermatomyositis: association with interstitial pulmonary disease. J Rheumatol. 1984 Oct;11(5):663–665. [PubMed] [Google Scholar]
  50. Ishida T., Matsumoto Y., Ohashi M., Sasaki R. Analysis of lymphocyte subpopulations in peripheral blood in adult and juvenile cases of dermatomyositis. J Dermatol. 1993 Jan;20(1):30–34. doi: 10.1111/j.1346-8138.1993.tb03825.x. [DOI] [PubMed] [Google Scholar]
  51. Ishida T., Ohashi M., Matsumoto Y., Morikawa J., Sasaki R. Connection of atopic disease in Japanese patients with juvenile dermatomyositis based on serum IgE levels. Clin Rheumatol. 1993 Mar;12(1):41–48. doi: 10.1007/BF02231557. [DOI] [PubMed] [Google Scholar]
  52. Jablonska S., Chorzelski T. P., Blaszczyk M., Jarzabek-Chorzelska M., Kumar V., Beutner E. H. Scleroderma/polymyositis overlap syndromes and their immunologic markers. Clin Dermatol. 1992 Oct-Dec;10(4):457–472. doi: 10.1016/0738-081x(92)90091-c. [DOI] [PubMed] [Google Scholar]
  53. Joffe M. M., Love L. A., Leff R. L., Fraser D. D., Targoff I. N., Hicks J. E., Plotz P. H., Miller F. W. Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy. Am J Med. 1993 Apr;94(4):379–387. doi: 10.1016/0002-9343(93)90148-i. [DOI] [PubMed] [Google Scholar]
  54. Jones B. F., Howarth D. M., Levi C. R., Glass J. S. Proteinuria in polymyositis. J Rheumatol. 1990 Jun;17(6):859–860. [PubMed] [Google Scholar]
  55. Kagan L. J. Myoglobinemia in inflammatory myopathies. JAMA. 1977 Apr 4;237(14):1448–1452. doi: 10.1001/jama.237.14.1448. [DOI] [PubMed] [Google Scholar]
  56. Kagen L. J., Aram S. Creatine kinase activity inhibitor in sera from patients with muscle disease. Arthritis Rheum. 1987 Feb;30(2):213–217. doi: 10.1002/art.1780300212. [DOI] [PubMed] [Google Scholar]
  57. Kagen L. J. Myoglobin: methods and diagnostic uses. CRC Crit Rev Clin Lab Sci. 1978;9(4):273–302. doi: 10.3109/10408367809150922. [DOI] [PubMed] [Google Scholar]
  58. Keshgegian A. A., Feinberg N. V. Serum creatine kinase MB isoenzyme in chronic muscle disease. Clin Chem. 1984 Apr;30(4):575–578. [PubMed] [Google Scholar]
  59. Kissel J. T., Mendell J. R., Rammohan K. W. Microvascular deposition of complement membrane attack complex in dermatomyositis. N Engl J Med. 1986 Feb 6;314(6):329–334. doi: 10.1056/NEJM198602063140601. [DOI] [PubMed] [Google Scholar]
  60. Kroll M., Otis J., Kagen L. Serum enzyme, myoglobin and muscle strength relationships in polymyositis and dermatomyositis. J Rheumatol. 1986 Apr;13(2):349–355. [PubMed] [Google Scholar]
  61. Lang B. A., Laxer R. M., Murphy G., Silverman E. D., Roifman C. M. Treatment of dermatomyositis with intravenous gammaglobulin. Am J Med. 1991 Aug;91(2):169–172. doi: 10.1016/0002-9343(91)90010-u. [DOI] [PubMed] [Google Scholar]
  62. Larca L. J., Coppola J. T., Honig S. Creatine kinase MB isoenzyme in dermatomyositis: a noncardiac source. Ann Intern Med. 1981 Mar;94(3):341–343. doi: 10.7326/0003-4819-94-3-341. [DOI] [PubMed] [Google Scholar]
  63. Lee K. N., Csako G., Bernhardt P., Elin R. J. Relevance of macro creatine kinase type 1 and type 2 isoenzymes to laboratory and clinical data. Clin Chem. 1994 Jul;40(7 Pt 1):1278–1283. [PubMed] [Google Scholar]
  64. Leff R. L., Burgess S. H., Miller F. W., Love L. A., Targoff I. N., Dalakas M. C., Joffe M. M., Plotz P. H. Distinct seasonal patterns in the onset of adult idiopathic inflammatory myopathy in patients with anti-Jo-1 and anti-signal recognition particle autoantibodies. Arthritis Rheum. 1991 Nov;34(11):1391–1396. doi: 10.1002/art.1780341108. [DOI] [PubMed] [Google Scholar]
  65. Lim R., Parker J. L. Apparent haematuria: an early sign in polymyositis. Br Med J (Clin Res Ed) 1988 Jun 18;296(6638):1725–1726. doi: 10.1136/bmj.296.6638.1725. [DOI] [PMC free article] [PubMed] [Google Scholar]
  66. Lisak R. P., Zweiman B. Serum immunogloblin levels in myasthenia gravis, polymyositis, and dermatomyositis. J Neurol Neurosurg Psychiatry. 1976 Jan;39(1):34–37. doi: 10.1136/jnnp.39.1.34. [DOI] [PMC free article] [PubMed] [Google Scholar]
  67. Lott J. A., Abbott L. B. Creatine kinase isoenzymes. Clin Lab Med. 1986 Sep;6(3):547–576. [PubMed] [Google Scholar]
  68. Love L. A., Leff R. L., Fraser D. D., Targoff I. N., Dalakas M., Plotz P. H., Miller F. W. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore) 1991 Nov;70(6):360–374. doi: 10.1097/00005792-199111000-00002. [DOI] [PubMed] [Google Scholar]
  69. Love L. A., Miller F. W. Noninfectious environmental agents associated with myopathies. Curr Opin Rheumatol. 1993 Nov;5(6):712–718. doi: 10.1097/00002281-199305060-00004. [DOI] [PubMed] [Google Scholar]
  70. Lovece S., Kagen L. J. Sensitive rapid detection of myoglobin in serum of patients with myopathy by immunoturbidimetric assay. J Rheumatol. 1993 Aug;20(8):1331–1334. [PubMed] [Google Scholar]
  71. Mandell B. F. Aldolase in the diagnosis of myositis. Am J Med. 1991 May;90(5):662–662. [PubMed] [Google Scholar]
  72. Marguerie C., Bunn C. C., Beynon H. L., Bernstein R. M., Hughes J. M., So A. K., Walport M. J. Polymyositis, pulmonary fibrosis and autoantibodies to aminoacyl-tRNA synthetase enzymes. Q J Med. 1990 Oct;77(282):1019–1038. doi: 10.1093/qjmed/77.1.1019. [DOI] [PubMed] [Google Scholar]
  73. Marguerie C., Bunn C. C., Copier J., Bernstein R. M., Gilroy J. M., Black C. M., So A. K., Walport M. J. The clinical and immunogenetic features of patients with autoantibodies to the nucleolar antigen PM-Scl. Medicine (Baltimore) 1992 Nov;71(6):327–336. doi: 10.1097/00005792-199211000-00001. [DOI] [PubMed] [Google Scholar]
  74. Medsger T. A., Jr, Dawson W. N., Jr, Masi A. T. The epidemiology of polymyositis. Am J Med. 1970 Jun;48(6):715–723. doi: 10.1016/s0002-9343(70)80006-7. [DOI] [PubMed] [Google Scholar]
  75. Miller F. W. Classification and prognosis of inflammatory muscle disease. Rheum Dis Clin North Am. 1994 Nov;20(4):811–826. [PubMed] [Google Scholar]
  76. Miller F. W., Love L. A., Barbieri S. A., Balow J. E., Plotz P. H. Lymphocyte activation markers in idiopathic myositis: changes with disease activity and differences among clinical and autoantibody subgroups. Clin Exp Immunol. 1990 Sep;81(3):373–379. doi: 10.1111/j.1365-2249.1990.tb05341.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  77. Miller F. W. Myositis-specific autoantibodies. Touchstones for understanding the inflammatory myopathies. JAMA. 1993 Oct 20;270(15):1846–1849. doi: 10.1001/jama.270.15.1846. [DOI] [PubMed] [Google Scholar]
  78. Miller F. W., Twitty S. A., Biswas T., Plotz P. H. Origin and regulation of a disease-specific autoantibody response. Antigenic epitopes, spectrotype stability, and isotype restriction of anti-Jo-1 autoantibodies. J Clin Invest. 1990 Feb;85(2):468–475. doi: 10.1172/JCI114461. [DOI] [PMC free article] [PubMed] [Google Scholar]
  79. Miller F. W., Waite K. A., Biswas T., Plotz P. H. The role of an autoantigen, histidyl-tRNA synthetase, in the induction and maintenance of autoimmunity. Proc Natl Acad Sci U S A. 1990 Dec;87(24):9933–9937. doi: 10.1073/pnas.87.24.9933. [DOI] [PMC free article] [PubMed] [Google Scholar]
  80. Mimori T., Hardin J. A., Steitz J. A. Characterization of the DNA-binding protein antigen Ku recognized by autoantibodies from patients with rheumatic disorders. J Biol Chem. 1986 Feb 15;261(5):2274–2278. [PubMed] [Google Scholar]
  81. Mimori T., Hinterberger M., Pettersson I., Steitz J. A. Autoantibodies to the U2 small nuclear ribonucleoprotein in a patient with scleroderma-polymyositis overlap syndrome. J Biol Chem. 1984 Jan 10;259(1):560–565. [PubMed] [Google Scholar]
  82. Misaki Y., Pruijn G. J., van der Kemp A. W., van Venrooij W. J. The 56K autoantigen is identical to human annexin XI. J Biol Chem. 1994 Feb 11;269(6):4240–4246. [PubMed] [Google Scholar]
  83. Montecucco C., Ravelli A., Caporali R., Viola S., De Gennaro F., Albani S., Martini A. Autoantibodies in juvenile dermatomyositis. Clin Exp Rheumatol. 1990 Mar-Apr;8(2):193–196. [PubMed] [Google Scholar]
  84. Moore E. C., Cohen F., Douglas S. D., Gutta V. Staphylococcal infections in childhood dermatomyositis--association with the development of calcinosis, raised IgE concentrations and granulocyte chemotactic defect. Ann Rheum Dis. 1992 Mar;51(3):378–383. doi: 10.1136/ard.51.3.378. [DOI] [PMC free article] [PubMed] [Google Scholar]
  85. Morton B. D., 3rd, Statland B. E. Serum enzyme alterations in polymyositis. Possible pitfalls in diagnosis. Am J Clin Pathol. 1980 Apr;73(4):556–557. doi: 10.1093/ajcp/73.4.556. [DOI] [PubMed] [Google Scholar]
  86. Newman A. J., Lee C. Hypothyroidism simulating dermatomyositis. J Pediatr. 1980 Nov;97(5):772–774. doi: 10.1016/s0022-3476(80)80263-0. [DOI] [PubMed] [Google Scholar]
  87. Newman E. D., Kurland R. J. P-31 magnetic resonance spectroscopy in polymyositis and dermatomyositis. Altered energy utilization during exercise. Arthritis Rheum. 1992 Feb;35(2):199–203. doi: 10.1002/art.1780350212. [DOI] [PubMed] [Google Scholar]
  88. Nicholson G. A., Morgan G. J., Meerkin M., Strauss E. R., McLeod J. G. The effect of aerobic exercise on serum creatine kinase activities. Muscle Nerve. 1986 Nov-Dec;9(9):820–824. doi: 10.1002/mus.880090905. [DOI] [PubMed] [Google Scholar]
  89. Nishikai M., Homma M. Circulating autoantibody against human myoglobin in polymyositis. JAMA. 1977 Apr 25;237(17):1842–1844. [PubMed] [Google Scholar]
  90. Nishikai M., Reichlin M. Radioimmunoassay of serum myoglobin in polymyositis and other conditions. Arthritis Rheum. 1977 Nov-Dec;20(8):1514–1518. doi: 10.1002/art.1780200811. [DOI] [PubMed] [Google Scholar]
  91. Nuviala R. J., Roda L., Lapieza M. G., Boned B., Giner A. Serum enzymes activities at rest and after a marathon race. J Sports Med Phys Fitness. 1992 Jun;32(2):180–186. [PubMed] [Google Scholar]
  92. O'Hanlon T. P., Dalakas M. C., Plotz P. H., Miller F. W. Predominant TCR-alpha beta variable and joining gene expression by muscle-infiltrating lymphocytes in the idiopathic inflammatory myopathies. J Immunol. 1994 Mar 1;152(5):2569–2576. [PubMed] [Google Scholar]
  93. Oddis C. V., Medsger T. A. Current management of polymyositis and dermatomyositis. Drugs. 1989 Mar;37(3):382–390. doi: 10.2165/00003495-198937030-00007. [DOI] [PubMed] [Google Scholar]
  94. Oddis C. V., Medsger T. A., Jr, Cooperstein L. A. A subluxing arthropathy associated with the anti-Jo-1 antibody in polymyositis/dermatomyositis. Arthritis Rheum. 1990 Nov;33(11):1640–1645. doi: 10.1002/art.1780331106. [DOI] [PubMed] [Google Scholar]
  95. Oddis C. V., Medsger T. A., Jr Relationship between serum creatine kinase level and corticosteroid therapy in polymyositis-dermatomyositis. J Rheumatol. 1988;15(5):807–811. [PubMed] [Google Scholar]
  96. Oddis C. V., Okano Y., Rudert W. A., Trucco M., Duquesnoy R. J., Medsger T. A., Jr Serum autoantibody to the nucleolar antigen PM-Scl. Clinical and immunogenetic associations. Arthritis Rheum. 1992 Oct;35(10):1211–1217. doi: 10.1002/art.1780351014. [DOI] [PubMed] [Google Scholar]
  97. Oddis C. V. Therapy for myositis. Curr Opin Rheumatol. 1993 Nov;5(6):742–748. doi: 10.1097/00002281-199305060-00008. [DOI] [PubMed] [Google Scholar]
  98. Ohdama S., Takano S., Miyake S., Kubota T., Sato K., Aoki N. Plasma thrombomodulin as a marker of vascular injuries in collagen vascular diseases. Am J Clin Pathol. 1994 Jan;101(1):109–113. doi: 10.1093/ajcp/101.1.109. [DOI] [PubMed] [Google Scholar]
  99. Okada N., Mimori T., Mukai R., Kashiwagi H., Hardin J. A. Characterization of human autoantibodies that selectively precipitate the 7SL RNA component of the signal recognition particle. J Immunol. 1987 May 15;138(10):3219–3223. [PubMed] [Google Scholar]
  100. Osterman P. O., Askmark H., Wistrand P. J. Serum carbonic anhydrase III in neuromuscular disorders and in healthy persons after a long-distance run. J Neurol Sci. 1985 Oct;70(3):347–357. doi: 10.1016/0022-510x(85)90176-5. [DOI] [PubMed] [Google Scholar]
  101. Pachman L. M., Cooke N. Juvenile dermatomyositis: a clinical and immunologic study. J Pediatr. 1980 Feb;96(2):226–234. doi: 10.1016/s0022-3476(80)80807-9. [DOI] [PubMed] [Google Scholar]
  102. Pachman L. M., Friedman J. M., Maryjowski-Sweeney M. L., Jonnason O., Radvany R. M., Sharp G. C., Cobb M. A., Battles N. D., Crowe W. E., Fink C. W. Immunogenetic studies of juvenile dermatomyositis. III. Study of antibody to organ-specific and nuclear antigens. Arthritis Rheum. 1985 Feb;28(2):151–157. doi: 10.1002/art.1780280208. [DOI] [PubMed] [Google Scholar]
  103. Park J. H., Vansant J. P., Kumar N. G., Gibbs S. J., Curvin M. S., Price R. R., Partain C. L., James A. E., Jr Dermatomyositis: correlative MR imaging and P-31 MR spectroscopy for quantitative characterization of inflammatory disease. Radiology. 1990 Nov;177(2):473–479. doi: 10.1148/radiology.177.2.2217788. [DOI] [PubMed] [Google Scholar]
  104. Park J. H., Vital T. L., Ryder N. M., Hernanz-Schulman M., Partain C. L., Price R. R., Olsen N. J. Magnetic resonance imaging and P-31 magnetic resonance spectroscopy provide unique quantitative data useful in the longitudinal management of patients with dermatomyositis. Arthritis Rheum. 1994 May;37(5):736–746. doi: 10.1002/art.1780370519. [DOI] [PubMed] [Google Scholar]
  105. Plotz P. H., Dalakas M., Leff R. L., Love L. A., Miller F. W., Cronin M. E. Current concepts in the idiopathic inflammatory myopathies: polymyositis, dermatomyositis, and related disorders. Ann Intern Med. 1989 Jul 15;111(2):143–157. doi: 10.7326/0003-4819-111-2-143. [DOI] [PubMed] [Google Scholar]
  106. Plotz P. H. Not myositis. A series of chance encounters. JAMA. 1992 Oct 21;268(15):2074–2077. doi: 10.1001/jama.268.15.2074. [DOI] [PubMed] [Google Scholar]
  107. Raben N., Borriello F., Amin J., Horwitz R., Fraser D., Plotz P. Human histidyl-tRNA synthetase: recognition of amino acid signature regions in class 2a aminoacyl-tRNA synthetases. Nucleic Acids Res. 1992 Mar 11;20(5):1075–1081. doi: 10.1093/nar/20.5.1075. [DOI] [PMC free article] [PubMed] [Google Scholar]
  108. Rasmussen L. H., Madsen H. N., Ladefoged S. D. Creatine phosphokinase MB and lactate dehydrogenase isoenzyme 1 in polymyositis. Scand J Rheumatol. 1985;14(4):427–430. doi: 10.3109/03009748509102049. [DOI] [PubMed] [Google Scholar]
  109. Reed A. M., Pachman L., Ober C. Molecular genetic studies of major histocompatibility complex genes in children with juvenile dermatomyositis: increased risk associated with HLA-DQA1 *0501. Hum Immunol. 1991 Dec;32(4):235–240. doi: 10.1016/0198-8859(91)90085-n. [DOI] [PubMed] [Google Scholar]
  110. Reed A., Haugen M., Pachman L. M., Langman C. B. Abnormalities in serum osteocalcin values in children with chronic rheumatic diseases. J Pediatr. 1990 Apr;116(4):574–580. doi: 10.1016/s0022-3476(05)81605-1. [DOI] [PubMed] [Google Scholar]
  111. Reeves W. H. Antibodies to the p70/p80 (Ku) antigens in systemic lupus erythematosus. Rheum Dis Clin North Am. 1992 May;18(2):391–414. [PubMed] [Google Scholar]
  112. Reeves W. H., Nigam S. K., Blobel G. Human autoantibodies reactive with the signal-recognition particle. Proc Natl Acad Sci U S A. 1986 Dec;83(24):9507–9511. doi: 10.1073/pnas.83.24.9507. [DOI] [PMC free article] [PubMed] [Google Scholar]
  113. Reeves W. H., Satoh M., Wang J., Chou C. H., Ajmani A. K. Systemic lupus erythematosus. Antibodies to DNA, DNA-binding proteins, and histones. Rheum Dis Clin North Am. 1994 Feb;20(1):1–28. [PubMed] [Google Scholar]
  114. Reichlin M., Arnett F. C., Jr Multiplicity of antibodies in myositis sera. Arthritis Rheum. 1984 Oct;27(10):1150–1156. doi: 10.1002/art.1780271011. [DOI] [PubMed] [Google Scholar]
  115. Reichlin M., Maddison P. J., Targoff I., Bunch T., Arnett F., Sharp G., Treadwell E., Tan E. M. Antibodies to a nuclear/nucleolar antigen in patients with polymyositis overlap syndromes. J Clin Immunol. 1984 Jan;4(1):40–44. doi: 10.1007/BF00915286. [DOI] [PubMed] [Google Scholar]
  116. Rider L. G., Miller F. W., Targoff I. N., Sherry D. D., Samayoa E., Lindahl M., Wener M. H., Pachman L. M., Plotz P. H. A broadened spectrum of juvenile myositis. Myositis-specific autoantibodies in children. Arthritis Rheum. 1994 Oct;37(10):1534–1538. doi: 10.1002/art.1780371019. [DOI] [PubMed] [Google Scholar]
  117. Rosalki S. B. Serum enzymes in disease of skeletal muscle. Clin Lab Med. 1989 Dec;9(4):767–781. [PubMed] [Google Scholar]
  118. Rowell N. R., Fairris G. M. Biochemical markers of myositis in dermatomyositis. Clin Exp Dermatol. 1986 Jan;11(1):69–72. doi: 10.1111/j.1365-2230.1986.tb00426.x. [DOI] [PubMed] [Google Scholar]
  119. Römisch K., Webb J., Herz J., Prehn S., Frank R., Vingron M., Dobberstein B. Homology of 54K protein of signal-recognition particle, docking protein and two E. coli proteins with putative GTP-binding domains. Nature. 1989 Aug 10;340(6233):478–482. doi: 10.1038/340478a0. [DOI] [PubMed] [Google Scholar]
  120. Sanmartí R., Collado A., Gratacós J., Bedini J. L., Pañella D., Filella X., Llena J., Muñoz-Gomez J. Reduced activity of serum creatine kinase in rheumatoid arthritis: a phenomenon linked to the inflammatory response. Br J Rheumatol. 1994 Mar;33(3):231–234. doi: 10.1093/rheumatology/33.3.231. [DOI] [PubMed] [Google Scholar]
  121. Scott J. P., Arroyave C. Activation of complement and coagulation in juvenile dermatomyositis. Arthritis Rheum. 1987 May;30(5):572–576. doi: 10.1002/art.1780300513. [DOI] [PubMed] [Google Scholar]
  122. Sharp G. C., Irvin W. S., May C. M., Holman H. R., McDuffie F. C., Hess E. V., Schmid F. R. Association of antibodies to ribonucleoprotein and Sm antigens with mixed connective-tissue disease, systematic lupus erythematosus and other rheumatic diseases. N Engl J Med. 1976 Nov 18;295(21):1149–1154. doi: 10.1056/NEJM197611182952101. [DOI] [PubMed] [Google Scholar]
  123. Sharp G. C., Irvin W. S., Tan E. M., Gould R. G., Holman H. R. Mixed connective tissue disease--an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA). Am J Med. 1972 Feb;52(2):148–159. doi: 10.1016/0002-9343(72)90064-2. [DOI] [PubMed] [Google Scholar]
  124. Shima K. Human muscle carbonic anhydrase III (CA-III). Purification, immunohistochemical localization in the human skeletal muscle and its clinical application to the neuromuscular disease. Hokkaido Igaku Zasshi. 1984 Mar;59(2):98–116. [PubMed] [Google Scholar]
  125. Strauss K. W., Gonzalez-Buritica H., Khamashta M. A., Hughes G. R. Polymyositis-dermatomyositis: a clinical review. Postgrad Med J. 1989 Jul;65(765):437–443. doi: 10.1136/pgmj.65.765.437. [DOI] [PMC free article] [PubMed] [Google Scholar]
  126. Targoff I. N., Arnett F. C., Berman L., O'Brien C., Reichlin M. Anti-KJ: a new antibody associated with the syndrome of polymyositis and interstitial lung disease. J Clin Invest. 1989 Jul;84(1):162–172. doi: 10.1172/JCI114136. [DOI] [PMC free article] [PubMed] [Google Scholar]
  127. Targoff I. N., Arnett F. C. Clinical manifestations in patients with antibody to PL-12 antigen (alanyl-tRNA synthetase). Am J Med. 1990 Mar;88(3):241–251. doi: 10.1016/0002-9343(90)90149-8. [DOI] [PubMed] [Google Scholar]
  128. Targoff I. N., Arnett F. C., Reichlin M. Antibody to threonyl-transfer RNA synthetase in myositis sera. Arthritis Rheum. 1988 Apr;31(4):515–524. doi: 10.1002/art.1780310408. [DOI] [PubMed] [Google Scholar]
  129. Targoff I. N. Humoral immunity in polymyositis/dermatomyositis. J Invest Dermatol. 1993 Jan;100(1):116S–123S. doi: 10.1111/1523-1747.ep12356607. [DOI] [PubMed] [Google Scholar]
  130. Targoff I. N. Immune manifestations of inflammatory muscle disease. Rheum Dis Clin North Am. 1994 Nov;20(4):857–880. [PubMed] [Google Scholar]
  131. Targoff I. N., Johnson A. E., Miller F. W. Antibody to signal recognition particle in polymyositis. Arthritis Rheum. 1990 Sep;33(9):1361–1370. doi: 10.1002/art.1780330908. [DOI] [PubMed] [Google Scholar]
  132. Targoff I. N. Laboratory manifestations of polymyositis/dermatomyositis. Clin Dermatol. 1988 Apr-Jun;6(2):76–92. doi: 10.1016/0738-081x(88)90051-x. [DOI] [PubMed] [Google Scholar]
  133. Targoff I. N., Reichlin M. Measurement of antibody to Jo-1 by ELISA and comparison to enzyme inhibitory activity. J Immunol. 1987 May 1;138(9):2874–2882. [PubMed] [Google Scholar]
  134. Targoff I. N., Trieu E. P., Miller F. W. Reaction of anti-OJ autoantibodies with components of the multi-enzyme complex of aminoacyl-tRNA synthetases in addition to isoleucyl-tRNA synthetase. J Clin Invest. 1993 Jun;91(6):2556–2564. doi: 10.1172/JCI116493. [DOI] [PMC free article] [PubMed] [Google Scholar]
  135. Targoff I. N., Trieu E. P., Plotz P. H., Miller F. W. Antibodies to glycyl-transfer RNA synthetase in patients with myositis and interstitial lung disease. Arthritis Rheum. 1992 Jul;35(7):821–830. doi: 10.1002/art.1780350718. [DOI] [PubMed] [Google Scholar]
  136. Tokano Y., Kanai Y., Hashimoto H., Okumura K., Hirose S. Soluble interleukin 2 receptors in patients with polymyositis/dermatomyositis. Ann Rheum Dis. 1992 Jun;51(6):781–782. doi: 10.1136/ard.51.6.781. [DOI] [PMC free article] [PubMed] [Google Scholar]
  137. Tokano Y., Obara T., Hashimoto H., Okumura K., Hirose S. Soluble CD4, CD8 in patients with polymyositis/dermatomyositis. Clin Rheumatol. 1993 Sep;12(3):368–374. doi: 10.1007/BF02231582. [DOI] [PubMed] [Google Scholar]
  138. Tsung S. H., Huang T. Y., Lin J. I. CK-MB isoenzyme in patients with polymyositis. Am J Med Sci. 1982 May-Jun;283(3):174–177. doi: 10.1097/00000441-198205000-00011. [DOI] [PubMed] [Google Scholar]
  139. Tymms K. E., Beller E. M., Webb J., Schrieber L., Buchanan W. W. Correlation between tests of muscle involvement and clinical muscle weakness in polymyositis and dermatomyositis. Clin Rheumatol. 1990 Dec;9(4):523–529. doi: 10.1007/BF02030515. [DOI] [PubMed] [Google Scholar]
  140. Vignos P. J., Jr, Goldwyn J. Evaluation of laboratory tests in diagnosis and management of polymyositis. Am J Med Sci. 1972 Apr;263(4):291–308. doi: 10.1097/00000441-197204000-00012. [DOI] [PubMed] [Google Scholar]
  141. Wada K., Ueno S., Hazama T., Ogasahara S., Kang J., Takahashi M., Tarui S. Radioimmunoassay for antibodies to human skeletal muscle myosin in serum from patients with polymyositis. Clin Exp Immunol. 1983 May;52(2):297–304. [PMC free article] [PubMed] [Google Scholar]
  142. Wei N., Pavlidis N., Tsokos G., Elin R. J., Plotz P. H. Clinical significance of low creatine phosphokinase values in patients with connective tissue diseases. JAMA. 1981 Oct 23;246(17):1921–1923. [PubMed] [Google Scholar]
  143. Whitaker J. N., Engel W. K. Vascular deposits of immunoglobulin and complement in idiopathic inflammatory myopathy. N Engl J Med. 1972 Feb 17;286(7):333–338. doi: 10.1056/NEJM197202172860701. [DOI] [PubMed] [Google Scholar]
  144. Wilfert C. M., Buckley R. H., Mohanakumar T., Griffith J. F., Katz S. L., Whisnant J. K., Eggleston P. A., Moore M., Treadwell E., Oxman M. N. Persistent and fatal central-nervous-system ECHOvirus infections in patients with agammaglobulinemia. N Engl J Med. 1977 Jun 30;296(26):1485–1489. doi: 10.1056/NEJM197706302962601. [DOI] [PubMed] [Google Scholar]
  145. Wolf P. L., Lott J. A., Nitti G. J., Bookstein R. Changes in serum enzymes, lactate, and haptoglobin following acute physical stress in international-class athletes. Clin Biochem. 1987 Apr;20(2):73–77. doi: 10.1016/s0009-9120(87)80102-9. [DOI] [PubMed] [Google Scholar]
  146. Wolf R. E., Baethge B. A. Interleukin-1 alpha, interleukin-2, and soluble interleukin-2 receptors in polymyositis. Arthritis Rheum. 1990 Jul;33(7):1007–1014. doi: 10.1002/art.1780330713. [DOI] [PubMed] [Google Scholar]
  147. Worrall J. G., Phongsathorn V., Hooper R. J., Paice E. W. Racial variation in serum creatine kinase unrelated to lean body mass. Br J Rheumatol. 1990 Oct;29(5):371–373. doi: 10.1093/rheumatology/29.5.371. [DOI] [PubMed] [Google Scholar]
  148. Yaneva M., Arnett F. C. Antibodies against Ku protein in sera from patients with autoimmune diseases. Clin Exp Immunol. 1989 Jun;76(3):366–372. [PMC free article] [PubMed] [Google Scholar]
  149. Yaneva M., Wen J., Ayala A., Cook R. cDNA-derived amino acid sequence of the 86-kDa subunit of the Ku antigen. J Biol Chem. 1989 Aug 15;264(23):13407–13411. [PubMed] [Google Scholar]
  150. Zhang M., Zamore P. D., Carmo-Fonseca M., Lamond A. I., Green M. R. Cloning and intracellular localization of the U2 small nuclear ribonucleoprotein auxiliary factor small subunit. Proc Natl Acad Sci U S A. 1992 Sep 15;89(18):8769–8773. doi: 10.1073/pnas.89.18.8769. [DOI] [PMC free article] [PubMed] [Google Scholar]
  151. el Allaf M., Chapelle J. P., el Allaf D., Adam A., Faymonville M. E., Laurent P., Heusghem C. Differentiating muscle damage from myocardial injury by means of the serum creatine kinase (CK) isoenzyme MB mass measurement/total CK activity ratio. Clin Chem. 1986 Feb;32(2):291–295. [PubMed] [Google Scholar]

Articles from Clinical and Diagnostic Laboratory Immunology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES